ENANTA PHARMACEUTICALS INC (ENTA) › Shareholders' EquityENANTA PHARMACEUTICALS INC (ENTA) — Shareholders' EquityAnnual figures by period end, from SEC filings.2010-09-30: -$150.07M2011-09-30: -$131.96M2012-09-30: -$115.35M2013-09-30: $110.47M2014-09-30: $148.65M2015-09-30: $236.16M2016-09-30: $269.94M2017-09-30: $301.68M2018-09-30: $393.68M2019-09-30: $462.49M2020-09-30: $455.58M2021-09-30: $399.43M2022-09-30: $321.33M2023-09-30: $216.74M2024-09-30: $128.81M2025-09-30: $64.72M$64.72M2010-09-30Shareholders' Equity (USD)2025-09-30Period endedShareholders' EquityChange YoYSource filing2025-09-30$64.72M-49.8%2025-11-19Balance as of period end2024-09-30$128.81M-40.6%2025-11-19Balance as of period end2023-09-30$216.74M-32.6%2025-11-19Balance as of period end2022-09-30$321.33M-19.6%2025-11-19Balance as of period end2021-09-30$399.43M-12.3%2024-11-27Balance as of period end2020-09-30$455.58M-1.5%2023-11-22Balance as of period end2019-09-30$462.49M+17.5%2022-11-23Balance as of period end2018-09-30$393.68M+30.5%2021-11-24Balance as of period end2017-09-30$301.68M+11.8%2020-11-25Balance as of period end2016-09-30$269.94M+14.3%2019-11-27Balance as of period end2015-09-30$236.16M+58.9%2018-11-29Balance as of period end2014-09-30$148.65M+34.6%2017-12-11Balance as of period end2013-09-30$110.47M—2016-12-09Balance as of period end2012-09-30-$115.35M—2015-12-11Balance as of period end2011-09-30-$131.96M—2014-12-11Balance as of period end2010-09-30-$150.07M—2013-12-18Balance as of period endOther metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)